|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0009402,
umls-concept:C0016360,
umls-concept:C0022277,
umls-concept:C0023413,
umls-concept:C0025677,
umls-concept:C0123931,
umls-concept:C0205179,
umls-concept:C0679729,
umls-concept:C1442457,
umls-concept:C1511237,
umls-concept:C1518578,
umls-concept:C1550436,
umls-concept:C1705509,
umls-concept:C1710133,
umls-concept:C1883712,
umls-concept:C2603343
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2002-7-18
|
|
pubmed:abstractText |
The purpose of this study was to compare the activity and toxicity of the combination of irinotecan (IRI) plus folinic acid (FA)-modulated 5-fluorouracil (5-FU) i.v. bolus with a regimen of double modulation of 5-FU with methotrexate (MTX) and FA in patients with advanced colorectal carcinoma.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
pubmed-author:Associated Institutions of the Southern Italy Cooperative Oncology Group,
pubmed-author:BuzziFF,
pubmed-author:ComellaPP,
pubmed-author:CrucittaEE,
pubmed-author:De CataldisGG,
pubmed-author:De LuciaLL,
pubmed-author:De VitaFF,
pubmed-author:Del GaizoFF,
pubmed-author:FarrisAA,
pubmed-author:LannelliAA,
pubmed-author:MaiorinoLL,
pubmed-author:MancarellaSS,
pubmed-author:PalmeriSS,
pubmed-author:TafutoSS
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
866-73
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12123331-Adenocarcinoma,
pubmed-meshheading:12123331-Adult,
pubmed-meshheading:12123331-Aged,
pubmed-meshheading:12123331-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12123331-Biopsy, Needle,
pubmed-meshheading:12123331-Camptothecin,
pubmed-meshheading:12123331-Colorectal Neoplasms,
pubmed-meshheading:12123331-Disease-Free Survival,
pubmed-meshheading:12123331-Dose-Response Relationship, Drug,
pubmed-meshheading:12123331-Drug Administration Schedule,
pubmed-meshheading:12123331-Female,
pubmed-meshheading:12123331-Fluorouracil,
pubmed-meshheading:12123331-Humans,
pubmed-meshheading:12123331-Italy,
pubmed-meshheading:12123331-Leucovorin,
pubmed-meshheading:12123331-Male,
pubmed-meshheading:12123331-Methotrexate,
pubmed-meshheading:12123331-Middle Aged,
pubmed-meshheading:12123331-Neoplasm Staging,
pubmed-meshheading:12123331-Prognosis,
pubmed-meshheading:12123331-Remission Induction,
pubmed-meshheading:12123331-Survival Analysis,
pubmed-meshheading:12123331-Treatment Outcome
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Addition of either irinotecan or methotrexate to bolus 5-fluorouracil and high-dose folinic acid every 2 weeks in advanced colorectal carcinoma: a randomised study by the Southern Italy Cooperative Oncology Group.
|
|
pubmed:affiliation |
Division of Medical Oncology A, National Tumour Institute, Naples, Italy. pcomella@sirio-oncology.it
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial
|
